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Introduction
Percutaneous coronary interventions (PCI), like angio-
plasty or stents, are well established and reflected in
DRG payment. However, recent scientific evidence
s h o w st h a tas i g n i f i c a n tn u m ber of patients having so-
called intermediate stenoses (i.e., a stenosis diameter bt.
40%–70% of the total coronary calibre) do not necessa-
rily profit from PCI.
Ad i a g n o s t i ct e s t– the measurement of the coronary
flow reserve (FFR) is available. The FAME study (Frac-
tional Flow Reserve versus Angiography for Guiding Per-
cutaneous Coronary Intervention, Tonino et.al., N Engl J
Med 2009;360:213-24) showed that refusing PCI in an
intermediate stenosis where the FFR is > 0.8 results in
better outcomes than performing PCI. There is strong
evidence for using FFR before performing a PCI in an
intermediate stenosis.
On the other hand, FFR itself causes costs (approxi-
mately € 900). The procedure code for FFR is already
incorporated in the German DRG system, Version 2010.
The research questions in this setting were:
1) What would happen if cardiologists in a hospital
introduced FFR, as recommended in the FAME
study?
2) How would the number of PCIs change?
3) What effect would occur on the total reimburse-
ment in the cardiac catheterization laboratory?
Materials and methods
In order to answer the research questions posed above,
a proprietary computer-based simulation model was
designed. Based on a database containing approximately
1 million patient records from approximately 100 hospi-
tals for the year 2009, we retrospectively selected a
population of 22,484 patients who had received an
angiography, a percutaneous coronary intervention, or
other cardiac catheterization procedures, and who had
not had an acute myocardial infarction.
For this group, we calculated the proportion of patients
eligible for FFR, applying the criteria used in the FAME
study, and we compared this with the real documented
FFR use in this group from our database. We then added
the FFR code to all eligible patients and regrouped the
population with the G-DRG Grouper 2010. In our simu-
lation model, we also calculated the impact that FFR use
would have in avoiding stenting; i.e., in moving from
DRGs with stents to those without stents.
FFR should be limited to those cases of intermediate ste-
noses where the decision for or against PCI cannot be
taken without further diagnostics. We obtained an esti-
mate of the prevalence of intermediate stenoses in the
German patient population through a survey of a number
of hospitals. In addition, we took data from the literature
(Coronary Pressure 2nd edition, by Nico Pijls, Bernard De
Bruyne; Kluwer Academic Publishers 2000 - p. 27, fig. 3.1).
Results
As an intermediate result, we separated the DRGs by
checking whether or not FFR causes changes in the
DRG assignment. These results were used to participate
in the annual structured dialogue process of the InEK-
institute in Germany, and resulted in the application for
funding of FFR in one-day cases.
7,769 patients got a PCI (at least on lesion stented).
After running these patients through the model, and
based on the above assumptions of FFR eligibility, 4,506
of these patients should potentially undergo FFR. Based
on the FAME results, this would mean that 2,478
patients would, as a result of FFR, have one stenosis less
to be stented. This means that 882 patients still end up
Dr. Wilke - inspiring.health, Munich, Germany
Wilke and Grube BMC Health Services Research 2010, 10(Suppl 2):A23
http://www.biomedcentral.com/1472-6963/10/S2/A23
© 2010 Wilke and Grube; licensee BioMed Central Ltd.in a PCI-DRG, whereas 1,596 patients end up in a non-
PCI (diagnostic) DRG.
From 14,715 patients having no PCI in the historical
data, we excluded 75% having unsusceptible coronary
angiography results. Thus 3,679 should undergo FFR in
addition to the coronary angiography. From these again,
1,655 (based on FAME data) would have a hemodyna-
mically relevant stenosis and undergo PCI, which would
result in a different DRG. Running all cases through the
model we saw DRG-changes in 8,185 patients.
Economical Impact of Introducing FFR in Hospitals
Before FFR (original data), the 22,484 patients had
an average DRG price of € 2,490.33. After running
the simulation, we found an average DRG price of
€ 3,522.84 in those patients that had undergone FFR
and had further treatment (PCI, PCI of at least one
lesion, or no further PCI).
Looking at the average cost of FFR – which is
approximately € 1,000 – we can conclude that FFR is
well reflected in the G-DRG system 2010. Thus, clini-
cians in hospital can freely decide to use FFR according
to the current guidelines without feeling that there is a
substantial risk that the procedure will not be financed.
Conclusions
Looking at the results, we can answer the research ques-
tions as follows:
1) FFR seems to be covered in inpatient DRGs.
However, the results can vary when FFR is applied
on non-eligible patients, and the DRG distribution is
different from our sample.
2) By using FFR, the number of unnecessary PCIs
can be reduced by approximately 30%, which
enhances the quality of care for patients and saves
money for insurers.
3) In one-day cases, FFR is not yet funded
Moreover, we found:
1) Simulating the financial impact of a clinically
meaningful technology is feasible.
2) By using DRG routine data, and additional data
from clinical studies, the simulation of changes in
clinical behaviour can be done before investing in
new technology.
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